Stockreport

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Clearside Biomedical, Inc.  (CLSD) 
Last clearside biomedical, inc. earnings: 3/11 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.clearsidebio.com/investor-overview
PDF - CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existi [Read more]